Q1 Earnings Estimate for Evotec Issued By HC Wainwright

Evotec SE (NASDAQ:EVO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Evotec in a note issued to investors on Thursday, November 7th. HC Wainwright analyst D. Tsao expects that the company will post earnings of ($0.01) per share for the quarter. HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Evotec's Q2 2025 earnings at $0.01 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.02 EPS.

EVO has been the subject of several other reports. Jefferies Financial Group downgraded Evotec from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Morgan Stanley cut shares of Evotec from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $15.00 to $6.00 in a report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, Evotec currently has an average rating of "Hold" and an average target price of $5.93.

Evotec Stock Down 2.8 %

Shares of EVO traded down $0.12 on Friday, hitting $4.13. 188,533 shares of the stock traded hands, compared to its average volume of 116,174. Evotec has a one year low of $2.85 and a one year high of $12.00. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.83 and a quick ratio of 1.73. The business has a 50 day simple moving average of $3.51 and a 200 day simple moving average of $4.23.

Hedge Funds Weigh In On Evotec

A number of institutional investors and hedge funds have recently made changes to their positions in EVO. Vanguard Personalized Indexing Management LLC bought a new stake in Evotec during the second quarter valued at about $87,000. Clear Harbor Asset Management LLC bought a new position in shares of Evotec during the 3rd quarter valued at approximately $104,000. Cetera Advisors LLC purchased a new stake in Evotec in the 1st quarter worth approximately $188,000. Mediolanum International Funds Ltd bought a new stake in Evotec during the 3rd quarter worth approximately $512,000. Finally, DCF Advisers LLC lifted its holdings in Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after purchasing an additional 67,156 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company's stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.